ALLMedicine™ Myeloproliferative Disease Center
Research & Reviews 169 results
https://doi.org/10.1007/s12032-022-01714-y 10.1016/j.cellsig.2013.05.019 10.1111/j.1349-7006.2012.02346.x 10.2147/dddt.S80207 10.1002/ajh.25011 10.2147/tcrm.s3425 10.1371/journal.pone.0098859 10.1016/j.clml.2013.05.012 10.2147/dddt.S85050 10.1007/s40272-018-0319-8 10.1182/blood.V101.2.690 10.1182/blood-2007-08-109330 10.1182/blood-2009-10-248211 10.4161/cc.22387 10.1158/2159-8290.Cd-14-1490 10.4161/cc.22808 10.1128/mcb.01484-13 10.1016/j.tcb.2003.11.001 10.1038/srep44674 10.1016/j.critrevonc.2018.05.003 10.1158/0008-5472.Can-06-1586 10.1182/blood-2011-11-394346 10.1182/blood-2010-08-303099 10.1002/ajh.21380 10.1007/s13277-015-4015-9 10.3747/co.v18i2.391 10.1002/ajh.24423 10.1016/j.leukres.2010.04.016 10.5732/cjc.011.10327 10.1016/j.bbamcr.2013.06.028 10.7150/ijms.29134 10.7508/ibj.2016.01.009 10.4161/23723556.2014.975089 10.1074/jbc.M212328200 10.1186/s12890-015-0127-7 10.1038/s41598-017-03814-6 10.1038/cdd.2014.116 10.1038/nrm2199 10.4161/cbt.5.7.2969 10.1038/sj.cdd.4401984 10.1016/j.bbrc.2018.09.032 10.1369/jhc.5A6785.2005 10.1074/jbc.M704069200 10.3390/cancers10100344 10.18632/oncotarget.13086 10.1158/0008-5472.Can-07-0045 10.1053/j.gastro.2018.10.031 10.1038/s41467-019-13700-6 10.1155/2015/324815 10.1182/bloodadvances.2018020503
Medical Oncology (Northwood, London, England); Ozel B, Kipcak S et. al.
Jun 19th, 2022 - Chronic myeloid leukemia (CML) is a myeloproliferative disease that mediated by BCR/ABL oncogenic signaling. CML can be targeted with the imatinib, dasatinib, and nilotinib TKI inhibitors, the latter two of them have been approved for imatinib-res...
https://emedicine.medscape.com/article/988024-overview
Jun 3rd, 2022 - Background Myelodysplastic syndrome (MDS) in childhood is a diverse group of clonal bone marrow disorders characterized by peripheral cytopenia, dysplastic changes in the bone marrow, and ineffective hematopoiesis. MDS disorders have been referred...
http://emedicine.medscape.com/article/988024-overview
Jun 3rd, 2022 - Background Myelodysplastic syndrome (MDS) in childhood is a diverse group of clonal bone marrow disorders characterized by peripheral cytopenia, dysplastic changes in the bone marrow, and ineffective hematopoiesis. MDS disorders have been referred...
https://emedicine.medscape.com/article/1976592-overview
Jun 3rd, 2022 - Background Myelodysplastic syndrome (MDS) in childhood is a diverse group of clonal bone marrow disorders characterized by peripheral cytopenia, dysplastic changes in the bone marrow, and ineffective hematopoiesis. MDS disorders have been referred...
https://emedicine.medscape.com/article/988024-print
Jun 3rd, 2022 - Background Myelodysplastic syndrome (MDS) in childhood is a diverse group of clonal bone marrow disorders characterized by peripheral cytopenia, dysplastic changes in the bone marrow, and ineffective hematopoiesis. MDS disorders have been referred...
Guidelines 1 results
https://doi.org/10.1007/s00277-014-2224-8
Annals of Hematology; Kreher S, Ochsenreither S et. al.
Oct 14th, 2014 - Patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) like polycythemia vera and essential thrombocythemia are at increased risk of arterial and venous thrombosis. Strategies of prevention may consist of platelet aggreg...
Clinicaltrials.gov 13 results
https://clinicaltrials.gov/ct2/show/NCT04146038
May 17th, 2022 - PRIMARY OBJECTIVE: I. Determine the tolerability of the addition of standard dose salsalate to the standard treatment combination of venetoclax + hypomethylating agent (HMA) (decitabine or azacitidine [5-azacytidine]). SECONDARY OBJECTIVES: I. Det...
https://clinicaltrials.gov/ct2/show/NCT04994158
Aug 6th, 2021 - Splanchnic or abdominal vein thrombosis (SVT) comprises thrombosis of hepatic, portal, superior mesenteric, splenic vein in isolation or combination. It has a prevalence of 1-2% in the general population based on autopsy reports. However, 40-50% o...
https://clinicaltrials.gov/ct2/show/NCT03262974
Aug 3rd, 2021 - Introduction: Chronic myeloid leukaemia (CML) is a myeloproliferative disease with an incidence of one to two cases per 100,000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults. The introduction of imatinib,...
https://clinicaltrials.gov/ct2/show/NCT03977103
Jan 13th, 2020 - Improving cGvHD/disease free survival in patients with high-risk acute leukemias or other hematologic malignancy where HSCT is indicated with the use of a regulatory T cell based protocol. Hyper-fractionated Total Body Irradiation or Total Marrow ...
https://clinicaltrials.gov/ct2/show/NCT04053933
Aug 13th, 2019 - Study type An observational study conducted in different hematological centers in Belgium. Study objectives Primary objective: To assess the impact of newly started treatments on the QOL of patients suffering from myelodysplastic syndromes. Second...
News 6 results
https://www.onclive.com/view/breaking-down-the-epidemiology-of-aml
Apr 2nd, 2021 - Transcript: Richard F. Schlenk, MD: Acute myeloid leukemia [AML] is a hematological disease focused on myeloid cells. It’s characterized by different mutations, which occur in the hematopoietic stem cells but also the hematopoietic progenitor ...
https://www.onclive.com/view/somatic-mutations-could-predict-response-to-hypomethylating-agents-in-mds
Dec 20th, 2020 - Aziz Nazha, MD A biomarker model that incorporates the mutational status of multiple somatic genes could be used to predict response to hypomethylating agents for patients with myelodysplastic syndromes (MDS), according to findings from a small p...
https://www.mdedge.com/hematology-oncology/article/187211/transplantation/switch-may-increase-supply-hscs-cord-blood
HT Staff
Jul 15th, 2016 - Cord blood donation Photo courtesy of NHS Researchers have discovered a genetic switch that could increase the supply of hematopoietic stem cells (HSCs) derived from cord blood, according to a paper published in Cell Stem Cell. However, experiment.
https://www.medscape.com/viewarticle/558906_3
Results Optimization The important variables for the ACB-PCR assay to detect the V617F mutation were the annealing temperature, dNTP concentration, and primer concentration. The majority of the conditions were modeled from a previous ACB-PCR assay...
https://www.medscape.com/viewarticle/558906_1
Abstract and Introduction Abstract The point mutation 1849 (GAET) V617F in the JAK2gene occurs at high frequency in several chronic myeloproliferative diseases. Although a number of V617F mutation detection methods have been described, few are rea...
